WFTC’s Mission

We Fund The Cure was established with a focus on funding high-speed research for cancer and chronic diseases; with the goal of creating breakthrough clinical treatments by connecting grassroots funders with medical research innovators in a dynamic online community. We Fund The Cure was founded and granted US 501(c)(3) non-profit organization status in 2009.

It is a little known fact that 99% of donations to medical research provide no benefit to sufferers of cancer and chronic disease. This is because most donations go to “basic research” also known as laboratory research. This type of research has a 1 in 5000 success rate of bringing new treatments to market, and even then takes up to 20 years.

Conversely, We Fund The Cure focuses its efforts on “drug repurposing” or “off-label” research – finding new uses for old drugs. This process yields an astounding 1 in 3 success rate in making new treatments available. Even better, the results are rapid and discovery of new treatments takes as little as 2 – 4 years. There is no greater promising avenue of clinical research funding that can deliver real and rapid results to donors and their loved ones.

Since it’s inception We Fund The Cure has been instrumental in facilitating several non-profit research projects for such conditions as:

  • Crohn’s disease
  • Colitis
  • Liver cancer (children)
  • Liver cancer (adults)
  • Breast cancer
  • Prostate cancer
  • Non-healing wounds
  • Dry eye disease
  • Cataracts
  • Pterygium and pinguecula
  • Multiple sclerosis
  • Rheumatoid arthritis
  • Gout
  • Diabetic retinopathy
  • Diabetic nephropathy
  • Diabetic neuropathy
  • and more


We Fund The Cure is involved in facilitating and funding projects on three continents, with planned research projects on five continents in the coming year, pairing up with medical professionals and universities in leading institutions. Its past and existing research has been carried out in collaboration with researchers at:


Researchers who have a project they would like to have considered please follow this link.